**Joint British Association for Sexual Health and HIV and Royal College of Obstetricians and Gynaecologists national UK guideline for the management of Herpes Simplex Virus (HSV) in Pregnancy and the Neonate (2024 update)**

Emily Clarke1,2, Raj Patel,3,4, Dyan Dickins5, Katy Fidler6, Allan Jackson7, Margaret Kingston8, Christine Jones4,9, Hermione Lyall10, Marian Nicholson11, Emanuela Pelosi9, David Porter12, Gemma Powell13, Elizabeth Foley3,4

1. Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK
2. University of Liverpool, Liverpool, UK
3. Solent NHS Trust, Southampton, UK
4. University of Southampton, Southampton, UK
5. Liverpool Women’s NHS Foundation Trust, Liverpool, UK
6. Brighton and Sussex Medical School, University of Sussex, Falmer, UK
7. NHS Greater Glasgow and Clyde, Glasgow, UK
8. British Association for Sexual Health and HIV Clinical Excellence Group
9. University Hospital Southampton NHS Foundation Trust, Southampton, UK
10. Imperial College Healthcare NHS Trust, London, UK
11. Herpes Viruses Association, UK
12. Alder Hey Children’s NHS Foundation Trust, Liverpool, UK
13. Patient and public representative

With thanks to JN (patient and public representative who wishes to remain anonymous), and to Professor Saye Khoo (Professor of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK).

**What’s new in the 2024 Management of Genital Herpes in Pregnancy guideline**

The guidelines have been substantially revised and updates in brief include:

* Use of ulcer panel PCR testing for herpetic lesions in pregnancy.
* Antiviral suppressive therapy to start earlier at 32 weeks of pregnancy for all mothers and pregnant people requiring this, and at 22 weeks if there is a high risk of preterm delivery.
* Use of valaciclovir as an alternative to aciclovir for treatment and/or suppression of genital herpes in the pregnant woman or person.
* A new section on the use of serology in the third trimester, and virology involvement in writing this guideline.
* Expansion of the neonatal management section, including risk stratification to guide investigations and treatment.
* Increased focus on the importance of the multi-disciplinary team (MDT) to include genitourinary medicine (GUM) physicians, obstetricians and neonatologists with formal documentation of a birth and postnatal care plan.
* Expansion of the prevention of postnatal transmission section, including a new section on breastfeeding.
* A new section on the management of clinically or serodiscordant couples.

**1.Objective and scope**

The first joint British Association for Sexual Health and HIV (BASHH) and Royal College of Obstetricians and Gynaecologists (RCOG) guideline on the management of genital herpes in pregnancy was published in 2014, this updated guideline supersedes that of 2014.

For more detailed information on the general management of genital herpes infection in people who are not pregnant , please refer to the 2024 BASHH guideline on the management of genital herpes (1).

The scope of this guideline is the inpatient and outpatient management of genital herpes simplex virus infection in the antenatal, intrapartum and postnatal periods in mothers and pregnant people, and neonates. This updated guideline also includes the prevention of genital herpes infection in uninfected women and people during pregnancy. The population covered by this guideline includes all the routine antenatal and perinatal care that mothers and pregnant people and their babies should receive, including those mothers and pregnant people with a suspected or confirmed diagnosis of genital herpes simplex infection and those at risk of acquisition in primary or secondary care.

This guideline is aimed at healthcare professionals working in sexual health clinics, maternity units, and those working on postnatal wards and neonatal units in the UK. However, the principles of the recommendations should be adopted across all services, including community care.

**Stakeholder involvement**

This guideline has been developed by a writing group including clinicians working in the fields of genitourinary medicine, obstetrics, neonatology and virology, and patient and public representatives. Specific expertise was provided by members of the BASHH Herpes Simplex Advisory Panel, the RCOG and the Royal College of Paediatrics and Child Health (RCPCH). The guideline was posted on the BASHH and RCOG websites for a 2-month consultation period, with direct requests for external peer review made to key bodies including the RCPCH. The guideline has been reviewed by the BASHH Public Panel and piloted in a representative clinic.

The guideline writing process was overseen by the BASHH Clinical Effectiveness Group. This is the most recent update of the BASHH/RCOG national guideline first written in 2014.

**2. Search strategy**

This document was produced in accordance with the guidance set out in the BASHH Clinical Effectiveness Group’s (CEG’s) document ‘Framework for guideline development and assessment’ (available from: <http://www.bashh.org/guidelines>).

A literature search was performed using PubMed/MEDLINE, EMBASE, Google, The Cochrane Library and relevant guidelines from 2014 to 2023. A MEDLINE/PubMed and EMBASE search was carried out from 2014 to 2023 using the following search terms/Medical Subject Headings (MeSH): ‘HSV/herpes’, ‘genital ulcers’, ‘HSV/herpes pregnancy’, ‘neonatal HSV/herpes’, ‘HSV/herpes drugs’, ‘pregnancy complications: infectious’, ‘Herpes genitalis’ and ‘Herpes simplex diagnosis’, ‘HSV/herpes breastfeeding’. The search was limited to humans and the English language. For some specific recommendations, an additional MEDLINE/PubMed search was performed when necessary.

A Google search was performed in 2023 with the search term ‘HSV guideline(s)’ and all relevant documents of the first 150 search results were reviewed. A search of The Cochrane Library included the Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects and Cochrane Central Register of Controlled Trials. The following guidelines were reviewed in detail: 2017 European guideline for the management of genital herpes (2); 2024 BASHH guidance on the management of genital herpes (1). The members of the guideline development group selected studies relevant to the scope of the guideline. Article titles and abstracts were reviewed and if relevant the full-text article obtained. Priority was given to randomised controlled trial and systematic review evidence and, where possible, recommendations were made and graded based on the best available evidence (Appendix 1). In areas where evidence is lacking, recommendations based on consensus opinion within the writing group have been made.

**3. Background**

Neonatal herpes is a very rare but serious viral infection with a high morbidity and mortality (3). It is classified into three subgroups in the infant depending on the site of infection: disease localised to only skin, eye and/or mouth (SEM), local central nervous system (CNS) disease (encephalitis alone or with SEM lesions) or disseminated disease with multiple organ involvement.

Neonatal infection occurs as the result of an infection at the time of birth (85%) , in the immediate postnatal period (10%) or, very rarely, in utero (5)% - termed congenital herpes (4).

Although neonatal HSV infection is very rare, the suspicion of possible neonatal HSV infection in infants with compatible symptoms or risk factors for perinatal or postnatal exposure is much more common. Thus the demand for diagnostic investigation of possible neonatal HSV infection is significant.

**Disease localised to skin, eye and/or mouth (SEM)**

Infants who present with symptoms localised to the skin, eye or mouth alone have the best prognosis. They represent approximately 32% of neonatal herpes cases, with median presentation at 8 days of life (5). They typically present with vesicular lesions or ulcers on the skin, eye or mouth and have no CNS or visceral organ involvement (6).

With appropriate antiviral treatment to prevent progression, mortality is 0% and neurological and/or ocular morbidity is around 6% and more likely in those with at least 3 lesions or HSV-2 (7). However such infants are at risk of recurrent SEM disease during childhood, which may disrupt childcare and schooling, and may be misdiagnosed, for example, as recurrent varicella.

**Central nervous system disease / meningoencephalitis**

In the UK, 35% have CNS disease with a median presentation of 14 days (5). They may present with a variety of signs including lethargy, poor feeding, or seizures and may not have skin, eye and/or mouth lesions (6). Median admission CRP may not be raised and was 3.9mg/L in recent UK wide surveillance (5).

Prior to antiviral therapy, 50% of infants with CNS disease died within 1 year (8). With antiviral treatment, mortality from CNS disease is around 15% and more likely in those who are semi-comatose or comatose, in premature infants, and in those with delayed time to treatment (7). Neurological morbidity (including developmental delay, epilepsy, blindness and cognitive disabilities) is common at 64%, and more frequent in those with seizures, HSV-2 infection, and those with delayed time to antiviral treatment (6,7).

**Disseminated infection**

In the UK, 33% of infants with neonatal herpes have disseminated disease with a median presentation of 6 days (5). Multiple organs are involved and may include the liver, lungs and brain, and skin, eye and/or mouth symptoms may be absent. Features of dissemination are typically non-specific with only 18% presenting with fever and 79% presenting with ‘sepsis’ (5,6). Median admission CRP may not be significantly raised and was 20mg/L in recent UK wide surveillance (5).

Prior to antiviral therapy, 85% of infants with disseminated infection died within 1 year (8). Disseminated disease carries the worst prognosis – with appropriate antiviral treatment, mortality is still around 66% and more likely in those who are semi-comatose or comatose, have HSV pneumonitis, disseminated intravascular coagulopathy, are premature, or with delayed antiviral treatment (5,7). 41% of infants have long term morbidity and this is more likely in those with seizures, HSV-2 infection, or delayed antiviral treatment (7).

Recent UK surveillance data has demonstrated an overall mortality of 24% (all presentations of neonatal HSV). 33% of preterm infants died in comparison with 19% of term infants. Mortality was more frequent in those with HSV-2 than those with HSV-1 infection (68% versus 29%), although previous studies have suggested that mortality may be higher in those with HSV-1 infection (5,7).

**Incidence**

Neonatal herpes is very rare in the UK, but surveillance data suggests that the incidence may be rising. Active surveillance by the British Paediatric Surveillance Unit (BPSU) between 1986 and 1991 found 76 cases over the five-and-a-half-year surveillance period with an incidence of 1.65/100 000 live births annually (95% CI 1.3–2.0) (9). Subsequent surveillance from 2004 to 2006 showed an approximate doubling of incidence with 86 cases seen over the three-year surveillance period, incidence 3.58/100,000 (10). A single centre study in Nottingham in 2006-2013 found an incidence of 17.5/100 000 live births, suggesting an increase in neonatal herpes of almost 5 times the UK wide incidence previously published (11).Further surveillance by the BPSU between 2019-2022 reported 118 confirmed cases with 4 still pending and estimated incidence as 6.9/100,000 live births (5).

The incidence in the UK is around 50% of that reported from other European countries and the USA (12,13). In the USA, the average reported incidence is 10/100,000 or 1 in 10,000, but there is considerable variation between populations and rates of up to 1 in 7,500 have been reported in certain deprived inner-city populations, and 1 in 3,000 in Florida (14–16). Data from the USA and Europe (as in the UK) suggest that incidence of neonatal herpes may be increasing over time (13,17,18).

Recent data on seroprevalence of antibodies to HSV-1 and/or HSV-2 in mothers and pregnant people in the UK are lacking. However, studies in the USA and Europe suggest that antibodies to HSV-1 and -2 may be declining over time, rendering an increased number of mothers and pregnant people vulnerable to primary herpes acquisition during pregnancy (14,19,20). Over the last decade the incidence of primary genital herpes in women in the UK has remained fairly static, but reporting has been significantly affected by the impact of COVID on sexual health clinics (21).

**Aetiology**

Neonatal herpes may be caused by herpes simplex virus type 1 (HSV-1) or herpes simplex virus type 2 (HSV-2) as either viral type can cause genital herpes in mothers and pregnant people, and HSV-1 may also be acquired due to post-natal contact. In recent UK surveillance, approximately 52% of neonatal herpes is due to HSV-1 and 48% due to HSV-2 (5).

Most cases of neonatal herpes occur as a result of either direct contact with infected vaginal secretions at birth (75-85%) or postnatal acquisition (10-25%) which may occur as a result of exposure to oro-labial herpes infection, usually from a close relative, friend of the parents or possibly a health care worker (4,9,10,22). Trans-placental spread in viraemic mothers may very rarely cause in utero congenital herpes (5%) (4).

**Transmission**

Genital herpes infection is classified as follows (1):

* ***Initial episode***: First episode with either HSV-1 or HSV-2. Dependent on whether the individual has had prior exposure to the other type, this is further subdivided into:
  + ***Primary infection***: first infection with either HSV-1 or HSV-2 in an individual with no pre-existing antibodies to either type.
  + ***Non-primary infection***: first infection with either HSV-1 or HSV-2 in an individual with pre-existing antibodies to the other type.

An initial episode may not be recognized as such as only approximately one third of patients present with symptoms following acquisition (23,24). Therefore, what appears to be an initial episode may be a recurrent episode.

* ***Recurrent episode***: recurrence of clinical symptoms due to reactivation of pre-existent HSV-1 or HSV-2 infection after a period of latency.

Factors associated with transmission of neonatal herpes include the type (primary/non-primary or recurrent) and timing of maternal infection, the absence of transplacentally-acquired maternal neutralising antibodies, the duration of rupture of membranes before delivery, the mode of delivery, and the use of assistance (vacuum, forceps or fetal scalp electrodes) (25,26). The risk of transmission is greatest when mothers and pregnant people acquire a new infection (primary genital herpes) in the third trimester, particularly within 6 weeks of delivery, as viral shedding may persist and the baby is likely to be born before the development of protective maternal antibodies (25,26).

Rarely, congenital herpes may occur because of transplacental intrauterine infection. Case reports suggest that the skin, eyes and CNS may be affected and there may be fetal growth restriction or fetal death (4,27–29).

Although recurrent genital herpes is associated with a very low risk of neonatal herpes, recurrent herpes at the time of delivery, which is commonly asymptomatic or unrecognised, may cause neonatal herpes. HSV-2 type-specific antibody correlates with protection from severe neonatal HSV-2 in infants exposed to HSV-2 at birth (30).

Data from the USA suggest that around 2% of women acquire genital HSV infection in pregnancy and most of these maternal infections are asymptomatic or unrecognised (3,26). However, acquisition in the UK in pregnancy may vary markedly given differing rates of neonatal herpes between the UK and USA. It is difficult to distinguish clinically between recurrent and primary genital HSV infections, as many first noted episodes of HSV are not true primary infections (24).

***Transmission associated with prematurity***

In the UK, 7.4% of live births are preterm (<37 weeks) (31). Preterm infants are at higher risk of neonatal herpes as, if delivered before 32-34 weeks gestation, they may not have received sufficient maternal antibodies to be protective, even where the parent is HSV seropositive. Recent UK surveillance data shows that 32% of babies with neonatal herpes are born <37 weeks (compared to the 7.4% national average): 6% <28 weeks, 4% 28-31+6 weeks, 23% 32-36+6 weeks, 64% were term and 3% unknown gestation (5). Outcomes were worse in premature infants with 33% of those born <37 weeks gestation dying in comparison with 19% of term (>37 weeks) infants, with increasing mortality associated with reducing gestation (5). Disseminated herpes is more common in preterm infants and occurs mainly as a result of primary infection in mothers and pregnant people (5). Furthermore, disseminated herpes has the highest mortality, again mortality increases with reducing gestation (5).

Several studies have demonstrated that commencing prophylactic aciclovir or valaciclovir at 36 weeks in mothers and pregnant people with a history of genital herpes reduces maternal genital tract viral load and lesions at delivery (32–39). It is therefore proposed that maternal antiviral suppressive therapy may reduce neonatal herpes, but this has not been studied sufficiently to definitively demonstrate that this is the case (40,41). Recent UK surveillance BPSU demonstrates that 33% of all babies with neonatal HSV are born at or before 36 weeks and therefore would not benefit from suppressive aciclovir started at 36 weeks (5). One randomised controlled trial in Uganda of 200 pregnant women known to be HSV-2 seropositive (excluding those with active lesions at randomisation) demonstrated a significant reduction in preterm delivery in those commenced on aciclovir prophylaxis at 28 weeks compared to those commencing at 36 weeks (42). Birth cohort data have demonstrated no significant increase in major birth defects in infants exposed to aciclovir or valaciclovir in the first trimester (43,44).

Regarding risk benefit analysis of the timing of commencing antiviral prophylaxis in mothers and pregnant people known to have genital herpes in the UK population, where 23% of babies with neonatal herpes are born between 32-36+6 weeks gestation with only a further 4% born 28 to 31+6 weeks gestation, it is consensus opinion of the writing group that antiviral prophylaxis should be routinely offered from 32 weeks. This is a change from the previous guidance to start antiviral prophylaxis at 36 weeks. For those at significantly increased risk of preterm delivery, consensus opinion is to start antiviral prophylaxis from 22 weeks.

**Disseminated herpes infection and post-partum presentation in mothers and pregnant people**

In adults, disseminated herpes simplex infection is rare and may present with encephalitis, hepatitis, disseminated skin lesions, viral sepsis or a combination of these conditions. However, it has been more commonly reported in pregnancy, particularly in the immunocompromised. The mortality of the pregnant woman or person associated with this condition is high (45).

The adult may present unwell with HSV in pregnancy or in the days after delivery, with local or disseminated disease. Their infants may have been exposed to HSV viraemia via the placenta and /or early asymptomatic lesions via the birth canal and are also at risk of severe HSV disease and death. In babies for whom their previously pregnant mother or parent presents with primary HSV up to 4 weeks following birth, HSV testing and treatment of the infant must be initiated urgently.

All immunocompromised people (which may include those living with HIV with suppressed CD4 counts), are at increased risk of more severe and frequent symptomatic recurrent episodes of genital herpes during pregnancy and of asymptomatic shedding of HSV at term (46,47). As co-infection with HSV and HIV results in an increased replication of both viruses (48), there are concerns that genital reactivation of HSV may increase the risk of perinatal transmission of both HIV and HSV (46,47), although this has not been realised in practice in the UK.

For more detailed information on the diagnosis and management of HSV infection in adults, please refer to the 2024 BASHH guideline on the management of genital herpes (1). Detailed management of disseminated herpes simplex infections in adults is beyond the scope of this guideline, but in brief:

* Consider disseminated HSV in all unwell pregnant or perinatal women and people with a sepsis-like illness or with deranged or worsening liver function tests.
* Send samples of blood, skin lesions, CSF, and relevant bodily fluids for urgent HSV PCR as well as blood for HSV IgG (liaise directly with virology to ensure rapid testing).
* Commence high dose IV aciclovir (at a dose of 10mg/kg three times a day based on ideal body weight) urgently prior to receiving results, at doses in accordance with the BNF, taking into account renal function and other relevant co-morbidities (49).
* Liaise early with virology/microbiology/infectious diseases, and HDU/ ITU teams if deteriorating.
* Urgently inform the neonatal team to review, the infant should be managed as a highest risk neonatal case (see section ‘Management of the neonate’).

**4. Management of first episode genital herpes in mothers and pregnant people** **during pregnancy and within the 4 weeks following birth**

**Management points for acquisition at any gestation** (to be read in conjunction with the following relevant section for stage of gestation)

* At the first antenatal (booking) appointment (and later if appropriate), all mothers and pregnant people should have a discussion and be given information on infections that can impact on the baby in pregnancy or during birth (including herpes simplex virus) (50). This should take place regardless of whether they are known to have herpes simplex virus already, or not [IV, C].

Data on the impact of herpes simplex infection during pregnancy upon adverse pregnancy outcomes are varied. A meta-analysis found that herpes simplex virus infection during pregnancy increased the risk of spontaneous miscarriage, premature birth and stillbirth (51,52). However, a study specifically reviewing first trimester acquisition found no evidence of an increased risk of spontaneous miscarriage with primary genital herpes (53). Some studies have demonstrated increased perinatal morbidity (preterm labour and low birthweight), together with stillbirth (3,72), however this was not shown in other studies (52,73). No additional monitoring of such pregnancies is recommended.

There is no evidence of an increased risk of birth defects from maternal HSV infection (54–56),apart from rare cases of congenital herpes simplex infection where case reports suggest that the skin, eyes and CNS may be affected and there may be fetal growth restriction or fetal death (27–29).

* A careful history from mothers and pregnant people should be taken to identify any previous possible herpetic symptoms or diagnoses as per NICE guidance (50) [IV,C].
* Mothers and pregnant people with suspected genital herpes should be referred to a genitourinary medicine (GUM) physician who will confirm or refute the diagnosis, advise on management of genital herpes, and arrange a screen for other sexually transmitted infections [IV, C].
* Polymerase chain reaction (PCR) testing from ulcers should routinely include type specific HSV, varicella zoster virus (VZV) and *Treponema pallidum* for syphilis. Where available, enterovirus PCR should be considered, and (depending on risk factors) MPOX and LGV PCR may be considered in addition to testing for other tropical ulcerative diseases (57–61) [IV, C].
* Full screening for other sexually transmitted infections should also be undertaken including chlamydia, gonorrhoea, syphilis, HIV and (depending on risk factors) hepatitis B and C as per BASHH guidelines (62) [IV,C].
* Treatment should not be delayed whilst awaiting test results. Management of mothers and pregnant people should be in line with their clinical condition and will usually involve the use of oral (or intravenous for disseminated HSV at 10mg/kg three times a day based on ideal body weight) aciclovir in standard doses (400 mg three times daily, usually for 5 days) or oral valaciclovir (500mg twice daily, usually for 5 days) as per the BASHH guidelines (1). Immunosuppressed mothers and pregnant people will require higher doses for a longer duration as per the BASHH guidelines (1). Famciclovir should not be used in pregnancy due to lack of safety data (44) [III, B].

The use of antivirals is associated with a reduction in the duration and severity of symptoms and a decrease in the duration of viral shedding (32–39). A study from the USA found that having untreated genital HSV in the first or second trimester was associated with an increased risk of preterm delivery, but this association was not seen in women and people who were treated with antiviral medication (63). Aciclovir and valaciclovir are not licensed for use in pregnancy but are considered safe and have not been associated with an increased incidence of birth defects (43,44). Transient neonatal neutropenia (44,64–66) has been reported but no clinically significant adverse maternal or neonatal effects have been reported. Aciclovir and valaciclovir are well tolerated in pregnancy. For treatment courses no dose adjustment is necessary (67,68).

* Other management of the symptomatic first episode should be in line with BASHH guidelines and may include the use of supportive therapies including paracetamol and topical lidocaine 2% gel or 5% ointment (1). There is no evidence that either is harmful in pregnancy in standard doses [IV, C].
* Mothers and pregnant people with suspected genital herpes who are having midwifery-led care should be referred for review by an obstetrician and have review by a genitourinary medicine (GUM) physician. The neonatologist should also be informed, and a delivery and postnatal management plan documented involving genitourinary medicine, obstetrics and neonatal collaboration [IV, C].
* Following acquisition, suppressive antivirals should be recommended. These reduce asymptomatic HSV shedding and lesions at term, and may also reduce premature delivery, but have not been studied sufficiently to definitively demonstrate prevention of neonatal HSV disease (32–42). Aciclovir and valaciclovir have not been associated with an increase in major birth defects when given in pregnancy (43,44) and should be given at the following doses:
  + For all mothers and pregnant people: aciclovir 400 mg three times daily or valaciclovir 500mg two times daily from 32 weeks of gestation (67). In third trimester acquisition, it may be more convenient simply to continue the treatment dose antivirals until delivery, even if suppression is starting prior to 32 weeks [1b, A].
  + For all mothers and pregnant people assessed as being at high risk of premature delivery: aciclovir 400 mg two times daily or valaciclovir 500mg once daily from 22 weeks of gestation, followed by aciclovir 400 mg three times daily or valaciclovir 500mg two times daily from 32 weeks of gestation [Ib, A].
  + Should mothers and pregnant people experience frequent recurrences of genital herpes despite being adherent to a suppressive antiviral regimen, dose adjustment may be considered after discussion with a genitourinary medicine (GUM) physician. In these cases, the possibility of HSV resistance to aciclovir (although rare) should be considered and discussed with a virologist (1). Drug resistance testing may be obtained via the UK HSA laboratory at Collingdale and may be particularly considered for those who are immunosuppressed (including those with haemopoietic stem cell transplant, solid organ transplant or advanced HIV).
* Parents should be advised to seek urgent medical help if they have concerns regarding their baby in the first 6 weeks of life, and if they develop symptoms of:
  + Skin, eye and mucous membrane lesions.
  + Lethargy/irritability.
  + Poor feeding.
  + Fever [IV, C].
* Parents must be told to inform the doctor that they had genital herpes in pregnancy and that their symptomatic baby needs testing and treating for herpes infections unless another diagnosis is made [IV, C].
* Birthing mothers and parents who present with first episode genital herpes and /or disseminated HSV up to the 4 weeks following birth are likely to have been shedding at delivery. The adult may have been unwell without classical herpetic lesions. This places the baby at high risk of neonatal HSV, they should be managed as a highest risk neonatal case (see section ‘Management of the neonate’) [IV, C].

**Additional considerations for first or second trimester acquisition (until 27+6 weeks of gestation), including second trimester acquisition with delivery within 6 weeks of acquisition**

* Where the pregnant woman or person is not known to have both HSV-1 and HSV-2, HSV serology should be performed, and the result used to inform the management of pregnancy and the birth plan (a birth plan is available in appendix 3 but local birth plans informed by the BASHH guidelines may be used instead). Further information on HSV serology is found in the section ‘Serology in third trimester acquisition’ [IV, C].
* For mothers and pregnant people with first and second trimester acquisition of genital herpes who are not known to have both HSV-1 and HSV-2, a discussion should be had around considering avoiding sex in the third trimester, including sex with condoms and oral sex [IV, C]. This is to remove uncertainty about whether any lesions presenting in the third trimester are recurrences of their known HSV type or are an acquisition episode of the other type. Undertaking serology may avoid this discussion [IV, C].
* Providing that delivery does not ensue within the next 6 weeks the pregnancy should be managed expectantly, and vaginal delivery anticipated [IV, C]. However, if delivery ensues within 6 weeks of acquisition, Caesarean section should be the recommended mode of delivery as shedding may continue for up to 6 weeks, although it can last for longer than this. The risk of neonatal transmission of HSV is very high at 41% for those who have acquired primary herpes simplex in the third trimester and are shedding at the time of delivery (3,69–71) [IIb, B] and it is anticipated that these same (or higher) risks exist for those acquiring primary herpes simplex in the second trimester who deliver within 6 weeks of acquisition.

**Additional considerations for third trimester acquisition (from 28 weeks of gestation) and up to the 4 weeks following birth**

* HSV serology should be performed. Further information on HSV serology in the third trimester is found in the following section ‘Serology in third trimester acquisition’ [IV, C].
* Caesarean section should be the recommended mode of delivery for all people developing first primary/non-primary episode genital herpes in the third trimester, particularly those developing symptoms within 6 weeks of expected delivery as shedding may continue for up to 6 weeks, although it can last for longer than this. The risk of neonatal transmission of HSV is very high at 41% for those who have acquired primary herpes simplex in the third trimester and are shedding at the time of delivery (3,69–71) [IIb, B].

***Serology in third trimester acquisition***

It can be difficult to distinguish clinically between initial and recurrent genital HSV infections, as in up to 15% of cases where mothers and pregnant people present with a first episode of clinical HSV infection, it will actually be a recurrent infection (24). Serology may support identifying this, and therefore impact on pregnancy and birth management plans. The presence of antibodies of the same type as the HSV isolated from genital swabs would confirm this episode to be a recurrence rather than a primary infection and elective caesarean section would not be indicated to prevent neonatal transmission. HSV-1 serology does not differentiate between oro-labial and genital infection, but it is reasonable to assume that HSV-2 serology is consistent with genital infection (74).

* Further information on HSV serology is found in the BASHH herpes guidelines and these should be read in conjunction with this section (1) [IV, C].
* Until results are received, an initial plan of delivery should assume that all first episode lesions are primary/non-primary initial genital herpes. This plan can then be modified if HSV antibody test results subsequently confirm a recurrent, rather than primary/non-primary, infection [IV, C].
* As interpretation of serology is complex, results should be discussed with a virologist or a genitourinary medicine physician [IV, C].
* For people presenting with first episode genital herpes in the third trimester, type-specific HSV antibody testing (immunoglobulin G (IgG) assays differentiating HSV-1 from HSV-2 infections) should be performed. Although a negative type-common antibody test result (which do not differentiate between HSV-1 and -2) may be helpful, type specific testing should not be delayed while waiting for a negative type-common result as this may delay management decisions [III, B].
* Initial HSV-1 and HSV-2 infections can be identified by detecting seroconversion to IgG in paired serum samples. HSV serological testing on the antenatal booking bloods in addition to serology at the time of presentation is therefore helpful to confirm HSV antibody status when HSV-1 or -2 DNA is detected by PCR [IV, C].
* However, false positives and negatives may occur as people may fail to seroconvert, may serorevert, or may have reduced test sensitivity due to a number of factors (1,75–82) [III, B].
* As time to serology results may be prolonged in clinics without local HSV serology testing, clinicians should establish links with their laboratory service to ensure that timely results are available [IV, C].

**5. Management of mothers and pregnant people** **with a diagnosis of genital herpes prior to pregnancy, including those with recurrent herpes during pregnancy**

* At the first antenatal (booking) appointment (and later if appropriate), all mothers and pregnant people should have a discussion and be given information on infections that can impact on the baby in pregnancy or during birth (including herpes simplex virus) (50). This should take place regardless of whether they are known to have herpes simplex virus already, or not [IV, C].
* Mothers and pregnant people with a diagnosis of genital herpes prior to pregnancy should be informed that the risk of neonatal herpes is low, even if lesions are present at the time of delivery (0–3% for vaginal delivery) (70), and that there is no increase in the incidence of congenital abnormalities in the presence of recurrent genital herpes infection (83) [III, B].
* Mothers and pregnant people with a previous genital herpes diagnosis should be referred to a genitourinary medicine physician who will advise on management of genital herpes and arrange a screen for other sexually transmitted infections if required [IV, C].
* Mothers and pregnant people with a previous genital herpes diagnosis who are having midwifery-led care should be referred for review by an obstetrician and have review by a genitourinary medicine physician. The neonatologist should also be informed, and a delivery and postnatal management plan documented involving genitourinary medicine, obstetrics and neonatal collaboration [IV, C].
* Suppressive antivirals for all mothers and pregnant people with known genital herpes should be recommended regardless of whether HSV recurrences occur during pregnancy [IV, C]. These reduce asymptomatic HSV shedding and lesions at term, and may also reduce premature delivery, however maternal antiviral suppressive therapy has not been studied sufficiently to definitively demonstrate that it prevents neonatal HSV disease (32–42). Aciclovir and valaciclovir have not been associated with an increase in major birth defects when given in pregnancy (43,44) and should be given at the following doses:
  + For all mothers and pregnant people: aciclovir 400 mg three times daily or valaciclovir 500mg two times daily from 32 weeks of gestation (67).
  + For all mothers and pregnant people assessed as being at high risk of premature delivery: aciclovir 400 mg two times daily or valaciclovir 500mg once daily from 22 weeks of gestation, followed by aciclovir 400 mg three times daily or valaciclovir 500mg two times daily from 32 weeks of gestation (84) [Ib, A].
  + Should mothers and pregnant people experience frequent recurrences of genital herpes despite being adherent to a suppressive antiviral regimen, dose adjustment may be considered after discussion with a genitourinary medicine (GUM) physician. In these cases, the possibility of HSV resistance to aciclovir (although rare) should be considered and discussed with a virologist (1). Drug resistance testing may be obtained via the UK HSA laboratory at Collingdale and may be particularly considered for those who are immunosuppressed (including those with haemopoietic stem cell transplant, solid organ transplant or advanced HIV).
* For mothers and pregnant people with known genital herpes who are not known to have both HSV-1 and HSV-2, a discussion should be had around considering avoiding sex in the third trimester, including sex with condoms and oral sex [IV, C]. This is to remove uncertainty about whether any lesions presenting in the third trimester are recurrences of their known HSV type or are an acquisition episode of the other type. Undertaking serology in this situation may help clarify the situation and avoid the need for this discussion [IV, C].
* Vaginal delivery should be anticipated in the absence of other obstetric indications for caesarean section [IV, C].
* Parents should be advised to seek urgent medical help if they have concerns regarding their baby in the first 6 weeks of life, and if they develop symptoms of:
  + Skin, eye and mucous membrane lesions.
  + Lethargy/irritability.
  + Poor feeding.
  + Fever [IV, C].
* Parents must be told to inform the doctor that they had genital herpes in pregnancy and the baby needs testing and treating for herpes infections unless another diagnosis is made [IV, C].

**Managing recurrences in pregnancy**

* Polymerase chain reaction (PCR) testing from ulcers should routinely include type specific HSV, varicella zoster virus (VZV) and *Treponema pallidum* for syphilis. Where applicable, enterovirus PCR should be considered, and (depending on risk factors) MPOX and LGV PCR may be considered in addition to testing for other tropical ulcerative diseases (57–61). In the third trimester, the laboratory should be informed to enable rapid return of results. A clinically typical recurrence may be an acquisition episode of another HSV type, or indeed a different sexually transmitted infection [IV, C].
* Where the pregnant woman or person is not known to have both HSV-1 and HSV-2, HSV serology should be performed, and the result used to inform the management of pregnancy and the birth plan (a birth plan is available in appendix 3 but local birth plans informed by the BASHH guidelines may be used instead). Further information on HSV serology is found in the section ‘Serology in third trimester acquisition’ [IV, C].
* Most recurrent episodes of genital herpes are short-lasting and resolve within 7–10 days without antiviral treatment. Supportive treatment measures using saline bathing, topical lidocaine 2% gel or 5% ointment, and analgesia with where standard doses of paracetamol alone will usually suffice [IV, C].
* Where antiviral episodic treatment is required to manage symptoms, the risks, benefits and alternatives should be discussed with mothers and pregnant people. Use of antivirals should be in line with their clinical condition and will usually involve the use of oral aciclovir in standard doses for episodic treatment (400 mg three times daily, usually for 5 days) or oral valaciclovir (500mg twice daily, usually for 5 days) as per the BASHH guidelines (1). Immunosuppressed mothers and pregnant people will require higher doses for a longer duration as per the BASHH guidelines (1). Famciclovir should not be used in pregnancy due to lack of safety data (44) [IV, C].
* Where antiviral suppression is required for symptom management prior to 32 weeks, the risks, benefits and alternatives should be discussed with mothers and pregnant people. Suppression should be given as aciclovir 400 mg two times daily or valaciclovir 500mg once daily, followed by aciclovir 400 mg three times daily or valaciclovir 500mg two times daily from 32 weeks of gestation [IV, C].
* Other management aspects are discussed above in the ‘Management of mothers and pregnant people with a diagnosis of genital herpes prior to pregnancy, including those with recurrent herpes during pregnancy’ section [IV, C].

**6. Management of mothers and pregnant people** **with primary or recurrent genital lesions at the onset of labour or within the 4 weeks following birth**

**General management**

Management of mothers and pregnant people with genital herpes at the onset of labour will be based on clinical assessment as there will not be time for confirmatory laboratory testing.

* A careful history from mothers and pregnant people should be taken to identify any previous possible herpetic symptoms or diagnoses as per NICE guidance (50) [IV, C].
* Urgent referral should be made to a genitourinary medicine (GUM) physician, consultant obstetrician and neonatologist and an urgent delivery and postnatal management plan documented [IV, C].
* Polymerase chain reaction (PCR) testing from ulcers should routinely include type specific HSV, varicella zoster virus (VZV) and *Treponema pallidum* for syphilis. Where applicable, enterovirus PCR should be considered, and (depending on risk factors) MPOX and LGV PCR may be considered in addition to testing for other tropical ulcerative diseases (57–61). The laboratory should be informed to enable rapid return of results. Although results are unlikely to be available in time to impact on delivery decisions, they may influence management of the neonate [IV, C].
* HSV serology should be performed. Further information on HSV serology in the third trimester is found in the following section ‘Serology in third trimester acquisition’ [IV, C].
* Parents should be advised to seek urgent medical help if they have concerns regarding their baby in the first 6 weeks of life, and if they develop symptoms of:
  + Skin, eye and mucous membrane lesions.
  + Lethargy/irritability.
  + Poor feeding.
  + Fever [IV, C].
* Parents must be told to inform the doctor that they had genital herpes in pregnancy and the baby needs testing and treating for herpes infections unless another diagnosis is made [IV, C].

**First episode genital herpes at onset of labour** (to be read in conjunction with the general management section above)

Where primary episode genital herpes lesions are present at the time of delivery and the baby is delivered vaginally, the risk of neonatal herpes is estimated to be 41% (3,69–71). For non-primary episode (mother or pregnant person already has one type of herpes and has newly acquired the second type) genital herpes lesions at birth, the risk is estimated 25% (85). The risk of perinatal transmission depends on the timing of maternal acquisition of HSV, with the highest risk in infants born to people who have not completed HSV seroconversion during pregnancy (most commonly in the third trimester, within 6 weeks of delivery), and possibly those with low antibody avidity (86).

* Caesarean section should be recommended to all mothers and pregnant people presenting with primary/non-primary episode genital herpes lesions at the time of delivery, to reduce exposure of the fetus to HSV which may be present in maternal genital secretions [III, B]
* There is some evidence to suggest that the benefit of Caesarean section reduces if the membranes have been ruptured for greater than 4 hours (87). However, there may be some benefit in performing a Caesarean section even after this time interval, and Caesarean section should be expedited in mothers and pregnant people whose membranes have ruptured to ensure that delivery occurs within 4 hours where possible [III, B].
* For those who decline a Caesarean section and proceed with vaginal delivery:
  + Intravenous aciclovir should be given intrapartum to mothers and pregnant people (5 mg/kg every 8 hours) and subsequently to the neonate (intravenous aciclovir 20 mg/kg every 8 hours) (56,88). It is unknown whether this reduces the risk of neonatal HSV infection.
* For those who proceed with a Caesarean section, especially where the membranes have already ruptured:
  + Intravenous aciclovir should be considered intrapartum to mothers and pregnant people (5 mg/kg every 8 hours) and subsequently to the neonate (intravenous aciclovir 20 mg/kg every 8 hours) (56,88). It is unknown whether this reduces the risk of neonatal HSV infection.
* Mothers and previously pregnant people who present with first episode genital herpes and /or disseminated HSV up to the 4 weeks following birth are likely to have been shedding at delivery. The adult may have been unwell without classical herpetic lesions. This places the baby at high risk of neonatal HSV, they should be managed as a highest risk neonatal case (see section ‘Management of the neonate’) [IV, C].

**Recurrent genital herpes at onset of labour when primary/non-primary infection was acquired before the 3rd trimester or more than 6 weeks prior to delivery** (to be read in conjunction with the general management section above)

* Mothers and pregnant people presenting with recurrent genital herpes lesions at the onset of labour should be advised that the risk to the baby of neonatal herpes is low (0–3% for vaginal delivery) (70) [III, B].
* Vaginal delivery should be offered to mothers and pregnant people where there is confidence that genital herpes lesions noted at the onset of labour are associated with recurrent rather than primary/non-primary infection. Evidence from the Netherlands shows that a conservative approach, facilitating vaginal delivery in the presence of an anogenital lesion, has not been associated with a rise in the number of neonatal HSV cases (70) [III, B].
* Where suppressive antivirals for the pregnant woman or person with known genital herpes has been started earlier in pregnancy, these reduce asymptomatic HSV shedding and lesions at term, and may also reduce premature delivery. However maternal antiviral suppressive therapy has not been studied sufficiently to definitively demonstrate that it prevents neonatal HSV disease (32–42).
* Where mothers and pregnant people with only one known HSV type have remained sexually active in the third trimester, a risk assessment should be undertaken to determine whether this could be a primary episode of the other HSV type [IV, C].
* A Caesarean section delivery for the purpose of reducing the risk of herpes transmission should not be recommended in view of the very low risk. The final choice of vaginal delivery versus caesarean section should be made by the pregnant woman or person, who should be advised to base their decision on the very low risk of transmission set against any other obstetric risk factors and the risks associated with caesarean section in accordance with National Institute for Health and Care Excellence (NICE) intrapartum guidelines (89) and considering guidance from their obstetric team [IV, C].
* There is no evidence to guide the management of mothers and pregnant people with spontaneous rupture of membranes at term, but many clinicians will advise expediting delivery to minimise the duration of potential exposure of the fetus to HSV [IV, C].

**7. Genital herpes in preterm prelabour rupture of membranes (before 37+0 weeks of gestation)**

**Primary/non-primary genital herpes in preterm prelabour rupture of membranes (PPROM)**

* The premature neonate is at high risk of neonatal HSV, they should be managed as a highest risk neonatal case (see section ‘Management of the neonate’) [IV, C].
* There is limited evidence to inform best obstetric practice when PPROM is complicated by primary HSV infection. Management should be guided by multidisciplinary team discussion involving the obstetricians, neonatologists and genitourinary medicine (GUM) physicians and will depend on the gestation that PPROM occurred. A delivery and postnatal management plan should be documented [IV, C].
* If the decision is made for immediate delivery, then the anticipated benefits of Caesarean section will remain in reducing the risk of neonatal herpes. If there is initial conservative management, mothers and pregnant people should be recommended to receive intravenous aciclovir 5 mg/kg every 8 hours until delivery [IV, C].
* Prophylactic corticosteroids should be considered to reduce the implications of preterm delivery upon the infant as per NICE guidelines (90) [III, B]. Prophylactic corticosteroids have been demonstrated to decrease mortality, respiratory problems, cerebral bleeding and developmental delay. There are no data on any impact of corticosteroids on HSV acquisition.
* If delivery is indicated within 6 weeks of the primary infection, delivery by Caesarean section may still offer some benefit despite the prolonged rupture of membranes (91–93) [IV, C].

**Recurrent genital herpes in PPROM**

* The premature neonate is at high risk of neonatal HSV, they should be managed as a highest risk neonatal case (see section ‘Management of the neonate’) [IV, C].
* Management should be guided by multidisciplinary team discussion involving the obstetricians, neonatologists and genitourinary medicine (GUM) physicians and will depend on the gestation that PPROM occurred. A delivery and postnatal management plan should be documented [IV, C].
* When PPROM is encountered in the presence of recurrent genital herpes lesions, the risk of neonatal transmission depends on the gestation and whether transplacental transfer of maternal HSV antibody has occurred [IV, C].
* Antiviral suppression for mothers and pregnant people with oral aciclovir 400 mg three times daily or valaciclovir 500mg twice daily should be started and continued until delivery [Ib, A].
* In the case of PPROM before 34 weeks there is evidence to suggest that expectant management is appropriate (91). After this gestation, it is recommended that management is undertaken in accordance with relevant Royal College of Obstetricians and Gynaecologists (RCOG) guidelines on PPROM (94). Antenatal corticosteroid administration (95) should be considered to reduce neonatal morbidity and mortality. Outcomes are not materially influenced by the presence of recurrent genital herpes lesions (91,96) [III, B].

**8. Management of mothers and pregnant people** **living with HIV with HSV infection**

There is evidence that a correlation exists between an HSV-2 diagnosis and HIV vertical transmission. However, studies are difficult to interpret given that many did not adjust for antiretroviral therapy (ART) use, and an association is often not demonstrated in studies adjusting for effective ART (97,98). Genital shedding of HSV-2 or HSV ulceration at term has not been consistently associated with vertical transmission of HIV, and again many studies do not adjust for ART use among other important factors (47,99–103).

* Management of mothers and pregnant people living with HIV is now aligned with treatment for HIV negative women and people – refer to the relevant section of this guideline [IV, C].
* When considering mode of delivery, recommendations within this guideline, the British HIV Association HIV in pregnancy guideline, in addition to obstetric factors should be considered (104) [IV, C].

**9. Management of the neonate**

These guidelines are produced for the management of babies born to mothers and pregnant people with known previous genital HSV infection or suspected HSV genital infection at delivery. Management of infants suspected to have neonatal HSV but without a suspected parental risk are outside the scope of this guideline.

* All cases of possible neonatal HSV, irrespective of route of acquisition should be discussed with the regional Paediatric Infectious Diseases Team [IV, C].

**General management prior to delivery**

* At the first antenatal (booking) appointment (and later if appropriate), all mothers and pregnant people should have a discussion and be given information on infections that can impact on the baby in pregnancy or during birth (including herpes simplex virus) (50). This should take place regardless of whether they are known to have herpes simplex virus already, or not [IV, C].
* In all cases the neonatal team should be informed at an early stage and should contribute, with genitourinary medicine (GUM) physicians and obstetricians, to the counselling of mothers and pregnant people, and in documentation of a delivery and postnatal management plan. The management plan should include the timing of investigations and any treatment to be offered [IV, C].

**General management post delivery**

* In all cases urgently inform the neonatal team [IV, C].
* Undertake investigations and management as per the following investigations and management sections [IV, C].
* Where investigations are required, liaise with the laboratory team to ensure rapid return of results and support with interpretation of complex results by virologists [IV, C].

**Symptoms of neonatal HSV**

A high index of suspicion for HSV infection and rapid instigation of therapy are essential to successful management. This guideline is provided to support the care of mothers and pregnant people with known herpes infection, but most neonatal herpes presents in neonates born to mothers and pregnant people not known to have herpes infection.

Neonatal herpes may present as disease localised to only skin, eye and/or mouth (SEM), local central nervous system (CNS) disease (encephalitis alone or with SEM lesions) or disseminated disease with multiple organ involvement. Further information on these presentations is found in the ‘Background’ section of these guidelines. Symptoms which may indicate neonatal HSV infection are non-specific but include a progressive illness. Non-diagnostic associated symptoms may include:

* Poor feeding.
* Lethargy.
* Skin vesicles (present in approximately one third).
* Fever (present in approximately a quarter).
* Seizures.
* Changes in consciousness ranging from lethargy to coma.
* Liver dysfunction (more common in disseminated HSV) (5).
* Coagulopathy.
* Pneumonitis.
* Unwell birth mother or parent without known cause or with disseminated HSV.
* Although rare, neonatal herpes presenting in infants whose birthing mothers or people have received antiviral suppressive therapy, may have an atypical clinical presentation and drug resistance (41). Where drug resistance is suspected, discuss with a virologist and consider sending samples for drug resistance testing (available at the UK HAS laboratory at Collingdale).
* Any neonate under 4 weeks where blood cultures are being considered should be reviewed for possible viral sepsis including HSV and have a blood PCR sent (EDTA sample) [IV, C].
* All local sepsis and antibiotic guidelines should refer to when to test for HSV. Superficial swabs of skin lesions, conjunctiva, mouth and anus, as well as blood and (where appropriate) CSF should all be sent urgently for HSV PCR. The laboratory should be contacted to ensure urgent return of results [IV, C].

**Immediate investigations and management**

* All cases of possible neonatal HSV should be discussed urgently with the regional Paediatric Infectious Diseases Team [IV, C].
* Any positive HSV test from an infant must be managed as highest risk [IV, C].

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Risk** | **Highest** | **High** | **Low** | **Lowest** |
| **Delivery method** | All infants with symptoms consistent with HSV infection regardless of delivery method  Babies with any positive HSV test even if this is suspected to be detection of maternal HSV  Babies born by vaginal delivery in the presence of active **initial** herpes lesions  Birthing mother or parent systemically unwell with possible HSV  Birthing mother or parent presents post-partum with active primary herpes lesions within 4 weeks of delivery | Pregnant parent had an initial HSV infection within the previous 6 weeks and baby is asymptomatic and born by:   * Vaginal delivery   **OR**   * Caesarean section regardless of duration of rupture of membranes | Asymptomatic babies born by any delivery method in the presence of active **recurrent** herpes lesions  Asymptomatic babies born at <37 weeks by any delivery method with no active lesions at delivery and a history of HSV infection more than 6 weeks previously | Asymptomatic babies born at >37 weeks by any delivery method with (99) with no active lesions in birthing woman or person at delivery **AND a h**istory of HSV infection more than 6 weeks previously |
| **Clinical assessment** | Urgently inform the neonatal team  Urgent assessment soon after birth, bearing in mind that the presentation of neonatal HSV may be non-specific and that skin lesions may not be present  Isolate infant from other babies and nurse using barrier methods to reduce the risk of postnatal transmission to other babies. Isolation should continue until neonatal herpes has been excluded or treatment completed in the event of neonatal HSV being confirmed.  Ophthalmology review. | Urgently inform the neonatal team  Urgent assessment soon after birth bearing in mind that the presentation of neonatal HSV may be non-specific and that skin lesions may not be present. If evidence of neonatal HSV is found, investigate as per symptomatic infants.  Isolate infant from other babies and nurse using barrier methods to reduce the risk of postnatal transmission to other babies. Isolation should continue until neonatal herpes has been excluded or treatment completed in the event of neonatal HSV being confirmed. | Urgently inform the neonatal team  Urgent assessment soon after birth bearing in mind that the presentation of neonatal HSV may be non-specific and that skin lesions may not be present. If evidence of neonatal HSV is found, investigate as per symptomatic infants. | Inform the neonatal team  No investigations required  Normal postnatal with a neonatal examination at 24 hours of age, after which the baby can be discharged from the hospital if well and feeding is established |
| **Timing of investigations** | Urgent (note maternal or birth parent HSV may still be detected on surface swabs, and therefore should be repeated if taken <24 hours of life) | 24 hours post-delivery (note maternal or birth parent HSV may still be detected on surface swabs, and therefore should be repeated if taken <24 hours of life) | 24 hours post-delivery (note maternal or birth parent HSV may still be detected on surface swabs taken <24 hours of life) |  |
| **HSV PCR swab** | Any visible lesions  Throat swab  Nose swab  Conjunctival swabs  Rectal swab | Throat swab  Nose swab  Conjunctival swabs  Rectal swab | Throat swab  Nose swab  Conjunctival swabs  Rectal swab |  |
| **Bloods** | HSV PCR (1mL EDTA required) (note may take >24 hours for sufficient HSV replication to occur for a positive result to occur, and so a negative test does not exclude infection, may need to be repeated) (106)  Full blood count  Liver function tests  Coagulation screen | HSV PCR (1mL EDTA required) (note may take >24 hours for sufficient HSV replication to occur for a positive result to occur, and so a negative test does not exclude infection, may need to be repeated) (106)  Full blood count  Liver function tests  Coagulation screen | HSV PCR (1mL EDTA required) (note may take >24 hours for sufficient HSV replication to occur for a positive result to occur, and so a negative test does not exclude infection, may need to be repeated) (106) |  |
| **Lumbar puncture for CSF** | If clinically safe, undertake lumbar puncture for CSF and send for:   * HSV PCR * Protein * Glucose * Cell count, microscopy and culture | If clinically safe, undertake lumbar puncture for CSF and send for:   * HSV PCR * Protein * Glucose   Cell count, microscopy and culture |  |  |
| **Other tests** | As guided by the infant’s clinical condition (for example chest X-ray)  In cases where drug resistance is a concern, discuss with a virologist and consider sending samples for drug resistance testing (available at the UK HAS laboratory at Collingdale) |  |  |  |
| **Management** | Urgently start aciclovir 20mg/kg IV without waiting for results. In cases where there is concern around possible aciclovir resistance or there is a shortage of IV aciclovir, IV foscarnet or cidofovir may be considered.  Duration of treatment:   * All results are negative, and no other cause identified: 10 days * Skin, eye and mouth disease only: 14 days * CNS or disseminated disease, or no CNS obtainable but other positive HSV tests: 21 days. Send blood and CSF (if previously positive) on day 17-20 (near as possible to day 21 depending on duration of laboratory result return times) for HSV PCR to ensure negative prior to stopping treatment on day 21. If CSF remains positive, continue IV aciclovir for a further week and repeat blood and CSF prior to stopping IV aciclovir. IF a further positive test is obtained, provide a further week of IV aciclovir.   A long line may be considered to avoid extravasation of IV aciclovir.  Oral aciclovir prophylaxis at 300mg/m3 TDS for 6 months to start post IV therapy for all infants with CNS or disseminated disease and considered in infants with skin, eye and mouth disease to reduce risk of CNS recurrences. | Urgently start aciclovir 20mg/kg IV without waiting for results. In cases where there is concern around possible aciclovir resistance or there is a shortage of IV aciclovir, IV foscarnet or cidofovir may be considered.  Duration of treatment:   * All results are negative, and baby remains asymptomatic: 10 days * Positive skin swab from completely intact skin: 10 days. * Positive skin swabs from areas of trauma without vesicles should be treated as per highest risk. * If baby becomes symptomatic or if any test is positive manage as per highest risk   A long line may be considered to avoid extravasation of IV aciclovir. | If any HSV test is positive, manage as per highest risk |  |
| **Advice to parents and carers** | Practice good hand hygiene and take care to reduce risk of postnatal infection from maternal genital secretions or other sources including anyone with oral HSV-1.  Seek urgent medical help if they have concerns regarding their baby in the next 6 weeks, in particular:   * Skin, eye and mucous membrane lesions * Lethargy/irritability * Poor feeding * Fever | | | |

**10. Prevention of postnatal transmission and management of breastfeeding**

Neonatal infection mostly occurs as the result of an infection at the time of birth, but in 10-25% of cases, a possible post-natal source is identified. Postnatal acquisition (10-25%) may occur as a result of exposure to oro-labial herpes infection (cold sore) or herpetic whitlow (lesion on the finger), usually from a close relative, friend of the parents or possibly a health care worker (4,9,10,22).

Mothers and pregnant people **diagnosed with HSV at least three months previously are likely to have HSV antibodies which may persist in the neonate up to around 6 months of age, providing a significant degree of protection** (106)**.**

* Efforts to prevent postnatal transmission of HSV are important and advice should be given to the parents regarding this [IV, C].
* As oral herpetic lesions (cold sores) may be a source of neonatal herpes, the following advice should be given to pregnant parents to limit possible exposure to HSV during the first 4-6 weeks of life [IV, C]:
  + Everyone should wash their hands prior to touching the baby.
  + The baby should not be kissed by people who are not very close family members or carers of the baby.
  + Those kissing the baby should kiss the top of the baby’s head and avoid kissing near the baby’s mouth, nose and eyes (to avoid mucous membranes).
  + People with current cold sores should never kiss the baby, and those with a history of cold sores should avoid kissing the baby.
  + People with active herpes lesions at any site should avoid touching the baby unless they are very close family members or carers of the baby, and in this case, they should practice good hand hygiene.
* Health care professionals with current active lesions, or recurrent cold sores or herpetic whitlows who work on neonatal wards, other wards with babies <6 weeks of age, on delivery suite, or with immunosuppressed patients should liaise with their Occupational Health department and a risk reduction plan agreed [IV, C]. Great care should be taken to avoid transmission including covering lesions, careful hand hygiene, and consideration of antiviral suppression.

**Management of breastfeeding**

Breastfeeding contributes to the health of breastfeeding women and people, and their children in the short and longer term.

* Parents should be made aware of the benefits of breastfeeding, and advice given according to UK guidance (107–110) [III,B].

**Use of antivirals in breastfeeding women and people**

Aciclovir and valaciclovir are excreted in breast milk, but represent less than 1% of a therapeutic dose in the infant (111–113).The presence of aciclovir or valaciclovir in breast milk has not been demonstrated to be harmful to infants (111). Furthermore, aciclovir given orally to infants (at therapeutic doses) rarely causes serious side effects (114). The manufacturer advises caution with use of aciclovir or valaciclovir when breastfeeding, but this is not based on evidence of harm (115).

* When an antiviral is required by breastfeeding women and people, standard doses and durations of aciclovir or valaciclovir should be used as per the BASHH herpes guidelines (1) [IV, C].
* There are no human data on famciclovir in breastfeeding in humans (116),and famciclovir should therefore not be used [IV, C].

**Breastfeeding with current or previous herpetic ulcers on the breast**

Herpes DNA is detectable in breast milk (117),but is not believed to be a source of infection for nursing infants. However, in the rare situation of breastfeeding women and people having current or previous herpetic lesions **on** the breast, transmission of HSV to the infant is possible by direct or indirect contact with lesions. The greatest risk of neonatal herpes is in the first six weeks of life.

* Herpetic lesions on the breast may be easily mistaken for impetigo or eczema. Possible lesions should therefore be tested promptly for HSV. Case reports suggest that herpetic lesions on the breasts are more likely to be due to HSV-1 (118–120) [IV, C].
* In the presence of current herpetic ulcers on the breast, breastfeeding women and people should not breastfeed the infant from the affected breast and ensure that the infant does not touch the breast, until all lesions have healed [IV, C].
* Breast milk can be contaminated if it comes in contact with active herpetic lesions through touching the breast during hand expression or via the pump. Breastfeeding women and people should not feed the infant expressed breast milk from the affected breast until all lesions have healed. Expressed breast milk from the affected side should not be used. Breast pumps and bottles should be sterilised. Lesions on the affected breast should be completely covered to avoid transmission and good hand hygiene practices followed. Breastfeeding or expressing milk from the unaffected breast can continue [IV, C].
* Herpetic lesions should be reviewed by a clinician to ensure that they have healed and to confirm that the breastfeeding women and people can resume breastfeeding or expressing milk from the affected breast [IV, C].
* Some breastfeeding women and people may need additional support to maintain their milk production and may need to supplement with their expressed human milk (previously expressed milk or expressed milk from the unaffected breast) or formula while herpetic lesions on the breast are healing [IV, C].
* A first episode or recurrence of herpes on the breast should be treated with standard doses of aciclovir or valaciclovir as per the BASHH herpes guidelines (1) [IV, C].

There are no published data on asymptomatic shedding of HSV from the breast in those with a history of herpetic ulcers on the breast, but it may occur and may cause transmission. Asymptomatic shedding following a first episode of genital herpes is known to be significant, particularly in the first three months following herpes acquisition (121).

Mothers and pregnant people **diagnosed with HSV at least three months previously are likely to have HSV antibodies which may persist in the neonate up to around 6 months of age, providing a significant degree of protection** (106)**.** Guidelines from countries with high rates of neonatal herpes in comparison with the UK, do not address asymptomatic shedding and promote breastfeeding provided there are no active herpetic lesions on the breast (122).Transmission due to asymptomatic shedding in this situation is therefore likely to be very low. There are no data on the use of aciclovir or valaciclovir su**ppression therapy in this situation, but antiviral suppression is likely to reduce shedding.**

* After a first episode of herpes on the breast or where there are recurrent breast lesions, breastfeeding parents should continue with aciclovir or valaciclovir suppressive therapy at doses recommended in the BASHH herpes guidelines (1),for at least six months, or until the infant reaches the age of 6 months, whichever is longer [IV, C].
* **Where there is a history of previous breast ulcers, with no recurrences during breast feeding, breastfeeding parents may consider taking suppressive antivirals at doses as recommended in the** BASHH herpes guidelines (1),until the infant reaches the age of 6 weeks of life [IV, C].

1. **Management of clinically discordant couples**

* At the first antenatal (booking) appointment (and later if appropriate), all mothers and pregnant people should have a discussion with the booking midwife and be given information on infections that can impact on the baby in pregnancy or during birth (including herpes simplex virus) (50). This should take place regardless of whether they are known to have herpes simplex virus already, or not [IV, C].
* Couples where the pregnant woman or person has no history of previous genital ulceration, and the sexual partner is known or suspected to have a previous diagnosis of genital HSV should be considered to be clinically discordant [IV, C].
* Serology may help identify couples who are serodiscordant although multiple caveats to its reliability apply (more information is in the following section ‘Use of serology in clinically discordant couples’) [IV, C].
* Advice on reducing transmission risk in non-pregnant clinically discordant couples is found in the BASHH herpes guidelines and should be reviewed with these guidelines (1) [IV, C].

There are a lack of data on reducing transmission to mothers and pregnant people. Data on risk reduction in non-pregnant women and people may not be able to be extrapolated to the pregnant population, as mothers and pregnant people may be at increased risk of HSV acquisition, and it is possible that interventions to reduce risk of acquisition may be less effective in this situation.

* Several strategies may be implemented to reduce risk of acquisition to mothers and pregnant people, who should be advised to particularly avoid acquisition during the third trimester (as risk of neonatal herpes is increased), and in the two weeks prior to the third trimester (incubation period) [IV, C].
* Risk reduction options should be discussed with clinically discordant couples to ensure that couples can make an informed decision about which methods they wish to employ to attempt to reduce transmission risk [IV, C].
* Abstinence from sexual activity (including vaginal, anal and oral sex, and mutual masturbation) in the third trimester and the two weeks prior to this is likely to be the most effective way to reduce transmission risk, and this should be recommended to couples [IV, C].
* Where abstinence is unacceptable to couples, the following risk reduction strategies should be advised:
  + Selective abstinence during recurrences and prodromes.
  + Male condoms used consistently and correctly might reduce the risk of genital herpes transmission (123–126)
  + Antiviral suppression of the sexual partner with known HSV with aciclovir (400mg twice daily) or valaciclovir (500mg once daily) will suppress symptomatic and asymptomatic viral shedding and may reduce transmission risk (127–130),and this should be offered to all couples [IV, C].
* Mothers and pregnant people without known orolabial herpes should be advised to abstain from receptive oral sex during the third trimester, and the two weeks prior to this (due to the incubation period for presenting with first episode genital herpes) to reduce the risk of genital HSV infection [IV, C]. Undertaking serology in this situation may help guide the discussion.

**Use of serology in clinically discordant couples**

* Routine HSV-2 serologic screening of mothers and pregnant people is not recommended (131) [IV, C].
* In couples who are clinically discordant, undertake type-specific herpes serology in both the pregnant woman or person, and the partner known to have genital herpes [IV, C].
* When a pregnant woman or person is in a clinically discordant partnership and tests positive for HSV-2 on serology, manage as per recurrent disease. HSV-1 serology does not differentiate site of infection and so may indicate oro-labial infection or genital infection [IV, C].

Type-specific serologic tests may be useful for identifying mothers and pregnant people at risk for HSV infection acquisition due to having a clinically discordant sexual partner, to guide counselling to reduce acquisition risk. Serologic tests may also be useful for mothers and pregnant people with a history of genital ulceration with no confirmed diagnosis of genital herpes or another cause of the ulceration.

Interpretation of serology results is discussed in the BASHH Herpes guidelines and advice provided here should be reviewed with these guidelines (1).It is important to remember however that serology may be both falsely positive or negative, and positive predictive test value in people who have never had genital lesions may be low (131). Serology can therefore only be used to guide advice around prevention of transmission rather than provide an absolute guarantee of herpes status. Expert virologist advice around interpretation of serological results may be helpful to guide advice.

**12. Performance measures**

1. Mothers and pregnant people with genital ulcers should have an anogenital ulcer panel of PCR tests performed to include type specific HSV, and if appropriate varicella zoster virus (VZV) and *Treponema pallidum* for syphilis. Target 97%
2. At the first antenatal (booking) appointment (and later if appropriate), all mothers and pregnant people should have a discussion and be given information on infections that can impact on the baby in pregnancy or during birth (including herpes simplex virus) (50). This should take place regardless of whether they are known to have herpes simplex virus already, or not, and should attempt to identify known or possible genital herpes in the patient and potential serodiscordance with their partners. Target 97%
3. Pregnant women and people presenting with an initial episode of genital herpes should be commenced on acyclovir and referred promptly to a GUM service. If they are in active labour urgent GUM advice should be sought where this is available. Target 97%
4. Mothers and pregnant people with genital herpes should be provided with written information on genital herpes in pregnancy. Target 90%.

**References**

1. Patel R, Green J, Moran B, Clarke E, Seneviratne K, Evans C, et al. 2022 UK National Guideline for the Management of Anogenital Herpes. 2023; Available from: bashh.org

2. Patel R, Kennedy OJ, Clarke E, Geretti A, Nilsen A, Lautenschlager S, et al. 2017 European guidelines for the management of genital herpes. Int J STD AIDS. 2017 Dec;28(14):1366–79.

3. Brown ZA, Selke S, Zeh J, Kopelman J, Maslow A, Ashley RL, et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med. 1997 Aug 21;337(8):509–15.

4. Kimberlin DW. Herpes simplex virus infections of the newborn. Semin Perinatol. 2007 Feb;31(1):19–25.

5. British Paediatric Surveillance Unit. Annual Report 2022-2023. 2023; Available from: https://www.rcpch.ac.uk/work-we-do/bpsu/annual-reports

6. Corey L, Wald A. Maternal and Neonatal HSV Infections. N Engl J Med. 2009 Oct 1;361(14):1376–85.

7. Whitley R, Arvin A, Prober C, Corey L, Burchett S, Plotkin S, et al. Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med. 1991 Feb 14;324(7):450–4.

8. Whitley RJ, Nahmias AJ, Soong SJ, Galasso GG, Fleming CL, Alford CA. Vidarabine therapy of neonatal herpes simplex virus infection. Pediatrics. 1980 Oct;66(4):495–501.

9. Tookey P, Peckham CS. Neonatal herpes simplex virus infection in the British Isles. Paediatr Perinat Epidemiol. 1996 Oct;10(4):432–42.

10. British Paediatric Surveillance Unit, Royal College of Paediatrics and Child Health, Royal College of Paediatrics and Child Health. BPSU 21st Annual Report 2006-2007. 2007; Available from: https://www.rcpch.ac.uk/work-we-do/bpsu/annual-reports

11. Batra D, Davies P, Manktelow BN, Smith C. The incidence and presentation of neonatal herpes in a single UK tertiary centre, 2006-2013. Arch Dis Child. 2014 Oct;99(10):916–21.

12. Looker KJ, Magaret AS, May MT, Turner KME, Vickerman P, Newman LM, et al. First estimates of the global and regional incidence of neonatal herpes infection. Lancet Glob Health. 2017 Mar;5(3):e300–9.

13. Hemelaar SJAL, Poeran J, Steegers EAP, van der Meijden WI. Neonatal herpes infections in The Netherlands in the period 2006-2011. J Matern-Fetal Neonatal Med Off J Eur Assoc Perinat Med Fed Asia Ocean Perinat Soc Int Soc Perinat Obstet. 2015 May;28(8):905–9.

14. Patton ME, Bernstein K, Liu G, Zaidi A, Markowitz LE. Seroprevalence of Herpes Simplex Virus Types 1 and 2 Among Pregnant Women and Sexually Active, Nonpregnant Women in the United States. Clin Infect Dis Off Publ Infect Dis Soc Am. 2018 Oct 30;67(10):1535–42.

15. Matthias J, du Bernard S, Schillinger JA, Hong J, Pearson V, Peterman TA. Estimating Neonatal Herpes Simplex Virus Incidence and Mortality Using Capture-recapture, Florida. Clin Infect Dis Off Publ Infect Dis Soc Am. 2021 Aug 2;73(3):506–12.

16. Donda K, Sharma M, Amponsah JK, Bhatt P, Okaikoi M, Chaudhari R, et al. Trends in the incidence, mortality, and cost of neonatal herpes simplex virus hospitalizations in the United States from 2003 to 2014. J Perinatol Off J Calif Perinat Assoc. 2019 May;39(5):697–707.

17. van Oeffelen L, Biekram M, Poeran J, Hukkelhoven C, Galjaard S, van der Meijden W, et al. Update on Neonatal Herpes Simplex Epidemiology in the Netherlands: A Health Problem of Increasing Concern? Pediatr Infect Dis J. 2018 Aug;37(8):806–13.

18. Mahant S, Hall M, Schondelmeyer AC, Berry JG, Kimberlin DW, Shah SS, et al. Neonatal Herpes Simplex Virus Infection Among Medicaid-Enrolled Children: 2009-2015. Pediatrics. 2019 Apr;143(4):e20183233.

19. Puhakka L, Sarvikivi E, Lappalainen M, Surcel HM, Saxen H. Decrease in seroprevalence for herpesviruses among pregnant women in Finland: cross-sectional study of three time points 1992, 2002 and 2012. Infect Dis Lond Engl. 2016;48(5):406–10.

20. Delaney S, Gardella C, Saracino M, Magaret A, Wald A. Seroprevalence of herpes simplex virus type 1 and 2 among pregnant women, 1989-2010. JAMA. 2014 Aug 20;312(7):746–8.

21. UK Health Security Agency. Sexually Transmitted Infection in England, 2021. 2022 [Internet]. Available from: https://www.gov.uk/government/statistics/sexually-transmitted-infections-stis-annual-data-tables

22. Courts and Tribunals Judiciary. Courts and Tribunals Judiciary. 2023 [cited 2024 May 2]. Kimberley Sampson and Samantha Mulcahy: Prevention of future deaths report. Available from: https://www.judiciary.uk/prevention-of-future-death-reports/kimberley-sampson-and-samantha-mulcahy-prevention-of-future-deaths-report/

23. Langenberg AG, Corey L, Ashley RL, Leong WP, Straus SE. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med. 1999 Nov 4;341(19):1432–8.

24. Hensleigh PA, Andrews WW, Brown Z, Greenspoon J, Yasukawa L, Prober CG. Genital herpes during pregnancy: inability to distinguish primary and recurrent infections clinically. Obstet Gynecol. 1997 Jun;89(6):891–5.

25. Brown Z. Preventing herpes simplex virus transmission to the neonate. Herpes J IHMF. 2004 Aug;11 Suppl 3:175A-186A.

26. Brown ZA, Wald A, Morrow RA, Selke S, Zeh J, Corey L. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA J Am Med Assoc. 2003 Jan 8;289(2):203–9.

27. Diguet A, Patrier S, Eurin D, Chouchene S, Marpeau L, Laquerrière A, et al. Prenatal diagnosis of an exceptional intrauterine herpes simplex type 1 infection. Prenat Diagn. 2006 Feb;26(2):154–7.

28. Vasileiadis GT, Roukema HW, Romano W, Walton JC, Gagnon R. Intrauterine herpes simplex infection. Am J Perinatol. 2003 Feb;20(2):55–8.

29. Lee A, Bar-Zeev N, Walker SP, Permezel M. In utero herpes simplex encephalitis. Obstet Gynecol. 2003 Nov;102(5 Pt 2):1197–9.

30. Ashley RL, Dalessio J, Burchett S, Brown Z, Berry S, Mohan K, et al. Herpes simplex virus-2 (HSV-2) type-specific antibody correlates of protection in infants exposed to HSV-2 at birth. J Clin Invest. 1992 Aug;90(2):511–4.

31. Office for National Statistics. Birth characteristics in England and Wales: 2020. 2022; Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/livebirths/bulletins/birthcharacteristicsinenglandandwales/2020

32. Sheffield JS, Hollier LM, Hill JB, Stuart GS, Wendel GD. Acyclovir prophylaxis to prevent herpes simplex virus recurrence at delivery: a systematic review. Obstet Gynecol. 2003 Dec;102(6):1396–403.

33. Watts DH, Brown ZA, Money D, Selke S, Huang ML, Sacks SL, et al. A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery. Am J Obstet Gynecol. 2003 Mar;188(3):836–43.

34. Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD. Acyclovir suppression to prevent recurrent genital herpes at delivery. Infect Dis Obstet Gynecol. 2002 Jan;10(2):71–7.

35. Brocklehurst P, Kinghorn G, Carney O, Helsen K, Ross E, Ellis E, et al. A randomised placebo controlled trial of suppressive acyclovir in late pregnancy in women with recurrent genital herpes infection. Br J Obstet Gynaecol. 1998 Mar;105(3):275–80.

36. Scott LL, Sanchez PJ, Jackson GL, Zeray F, Wendel GD. Acyclovir suppression to prevent cesarean delivery after first-episode genital herpes. Obstet Gynecol. 1996 Jan;87(1):69–73.

37. Braig S, Luton D, Sibony O, Edlinger C, Boissinot C, Blot P, et al. Acyclovir prophylaxis in late pregnancy prevents recurrent genital herpes and viral shedding. Eur J Obstet Gynecol Reprod Biol. 2001 May;96(1):55–8.

38. Hollier LM, Wendel GD. Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infection. Cochrane Database Syst Rev Online. 2008 Jan;(1):CD004946.

39. Sheffield JS, Hill JB, Hollier LM, Laibl VR, Roberts SW, Sanchez PJ, et al. Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial. Obstet Gynecol. 2006 Jul;108(1):141–7.

40. James SH, Sheffield JS, Kimberlin DW. Mother-to-Child Transmission of Herpes Simplex Virus. J Pediatr Infect Dis Soc. 2014 Sep;3 Suppl 1(Suppl 1):S19-23.

41. Pinninti SG, Angara R, Feja KN, Kimberlin DW, Leach CT, Conrad DA, et al. Neonatal Herpes Disease following Maternal Antenatal Antiviral Suppressive Therapy: A Multicenter Case Series. J Pediatr. 2012 Jul;161(1):134-138.e3.

42. Nakubulwa S, Kaye DK, Bwanga F, Tumwesigye NM, Nakku-Joloba E, Mirembe F. Effect of suppressive acyclovir administered to HSV-2 positive mothers from week 28 to 36 weeks of pregnancy on adverse obstetric outcomes: a double-blind randomised placebo-controlled trial. Reprod Health. 2017 Mar 3;14(1):31.

43. Glaxo Wellcome. Acyclovir Pregnancy Registry and Valacyclovir Pregnancy Registry Interim Report. 1997; Available from: https://pregnancyregistry.gsk.com/acyclovir.html

44. Pasternak B, Hviid A. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA J Am Med Assoc. 2010 Aug 25;304(8):859–66.

45. Young EJ, Chafizadeh E, Oliveira VL, Genta RM. Disseminated herpesvirus infection during pregnancy. Clin Infect Dis Off Publ Infect Dis Soc Am. 1996 Jan;22(1):51–8.

46. Hitti J, Watts DH, Burchett SK, Schacker T, Selke S, Brown ZA, et al. Herpes simplex virus seropositivity and reactivation at delivery among pregnant women infected with human immunodeficiency virus-1. Am J Obstet Gynecol. 1997 Aug;177(2):450–4.

47. Chen KT, Segú M, Lumey LH, Kuhn L, Carter RJ, Bulterys M, et al. Genital herpes simplex virus infection and perinatal transmission of human immunodeficiency virus. Obstet Gynecol. 2005 Dec;106(6):1341–8.

48. Heng MC, Heng SY, Allen SG. Co-infection and synergy of human immunodeficiency virus-1 and herpes simplex virus-1. Lancet. 1994 Jan 29;343(8892):255–8.

49. BNF content published by NICE [Internet]. 2024 [cited 2024 May 2]. Available from: https://bnf.nice.org.uk/

50. National Institute for Health and Care Excellence. Antenatal care: NICE guideline NG201. 2021; Available from: https://www.nice.org.uk/guidance/ng201

51. Shi TL, Huang LJ, Xiong YQ, Zhong YY, Yang JJ, Fu T, et al. The risk of herpes simplex virus and human cytomegalovirus infection during pregnancy upon adverse pregnancy outcomes: A meta-analysis. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2018 Jul;104:48–55.

52. Syridou G, Spanakis N, Konstantinidou A, Piperaki ET, Kafetzis D, Patsouris E, et al. Detection of cytomegalovirus, parvovirus B19 and herpes simplex viruses in cases of intrauterine fetal death: association with pathological findings. J Med Virol. 2008 Oct;80(10):1776–82.

53. Zhou Y, Bian G, Zhou Q, Gao Z, Liao P, Liu Y, et al. Detection of cytomegalovirus, human parvovirus B19, and herpes simplex virus-1/2 in women with first-trimester spontaneous abortions. J Med Virol. 2015 Oct;87(10):1749–53.

54. Howley MM, Feldkamp ML, Papadopoulos EA, Fisher SC, Arnold KE, Browne ML, et al. Maternal genitourinary infections and risk of birth defects in the National Birth Defects Prevention Study. Birth Defects Res. 2018 Nov 15;110(19):1443–54.

55. Voekt CA, Rinderknecht T, Hirsch HH, Blaich A, Hösli IM. Ultrasound indications for maternal STORCH testing in pregnancy. Swiss Med Wkly. 2017;147:w14534.

56. Acs N, Bánhidy F, Puhó E, Czeizel AE. No association between maternal recurrent genital herpes in pregnancy and higher risk for congenital abnormalities. Acta Obstet Gynecol Scand. 2008 Jan;87(3):292–9.

57. Mariaggi AA, Boujenah J, L’Honneur AS, Carbillon L, Rozenberg F. Genital zoster in near term pregnancy: Case report and need of management guidelines. J Gynecol Obstet Hum Reprod. 2020 Feb;49(2):101675.

58. Magdaleno-Tapial J, Hernández-Bel P, Ortiz-Salvador JM, López-Martí C, Martínez-Doménech Á, García-Legaz-Martínez M, et al. Genital Herpes Zoster: A Rare Location That Can Mimic Genital Herpes. Sex Transm Dis. 2022 Jan 1;49(1):e34–6.

59. Integrated Screening Outcomes Surveillance Service (ISOSS). ISOSS congenital syphilis case review report: 2015 to 2020. 2021; Available from: https://www.gov.uk/government/publications/infectious-diseases-in-pregnancy-screening-isoss-congenital-syphilis-report-2015-to-2020/isoss-congenital-syphilis-case-review-report-2015-to-2020

60. Wong J, Langford A, Howard DL. Nonsexually Transmitted Genital Ulcer Secondary to Hand, Foot, and Mouth Disease. Obstet Gynecol. 2019 Jun;133(6):1269–73.

61. Howe B, Basta M, Foster K, Esen U, Ellis R, Hussey J. Primary syphilis in pregnancy mistaken for genital herpes: A preventable cause of congenital syphilis. Eur J Obstet Gynecol Reprod Biol. 2017 Dec;219:133.

62. BASHH Clincial Effectiveness Group. 2015 BASHH CEG guidance on tests for Sexually Transmitted Infections. 2015; Available from: https://www.bashhguidelines.org/media/1084/sti-testing-tables-2015-dec-update-4.pdf

63. Li DK, Raebel MA, Cheetham TC, Hansen C, Avalos L, Chen H, et al. Genital herpes and its treatment in relation to preterm delivery. Am J Epidemiol. 2014 Dec 1;180(11):1109–17.

64. Andrews WW, Kimberlin DF, Whitley R, Cliver S, Ramsey PS, Deeter R. Valacyclovir therapy to reduce recurrent genital herpes in pregnant women. Am J Obstet Gynecol. 2006 Mar;194(3):774–81.

65. Stone KM, Reiff-Eldridge R, White AD, Cordero JF, Brown Z, Alexander ER, et al. Pregnancy outcomes following systemic prenatal acyclovir exposure: Conclusions from the international acyclovir pregnancy registry, 1984-1999. Birt Defects Res A Clin Mol Teratol. 2004 Apr;70(4):201–7.

66. Ratanajamit C, Vinther Skriver M, Jepsen P, Chongsuvivatwong V, Olsen J, Sørensen HT. Adverse pregnancy outcome in women exposed to acyclovir during pregnancy: a population-based observational study. Scand J Infect Dis. 2003 Jan;35(4):255–9.

67. Frenkel LM, Brown ZA, Bryson YJ, Corey L, Unadkat JD, Hensleigh PA, et al. Pharmacokinetics of acyclovir in the term human pregnancy and neonate. Am J Obstet Gynecol. 1991 Feb;164(2):569–76.

68. Kimberlin DF, Weller S, Whitley RJ, Andrews WW, Hauth JC, Lakeman F, et al. Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy. Am J Obstet Gynecol. 1998 Oct;179(4):846–51.

69. Brown ZA, Vontver LA, Benedetti J, Critchlow CW, Sells CJ, Berry S, et al. Effects on infants of a first episode of genital herpes during pregnancy. N Engl J Med. 1987 Nov 12;317(20):1246–51.

70. Prober CG, Sullender WM, Yasukawa LL, Au DS, Yeager AS, Arvin AM. Low risk of herpes simplex virus infections in neonates exposed to the virus at the time of vaginal delivery to mothers with recurrent genital herpes simplex virus infections. N Engl J Med. 1987 Jan 29;316(5):240–4.

71. Brown ZA, Benedetti J, Ashley R, Burchett S, Selke S, Berry S, et al. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med. 1991 May 2;324(18):1247–52.

72. Brown ZA, Benedetti J, Selke S, Ashley R, Watts DH, Corey L. Asymptomatic maternal shedding of herpes simplex virus at the onset of labor: relationship to preterm labor. Obstet Gynecol. 1996 Apr;87(4):483–8.

73. Eskild A, Jeansson S, Stray-Pedersen B, Jenum PA. Herpes simplex virus type-2 infection in pregnancy: no risk of fetal death: results from a nested case-control study within 35,940 women. BJOG Int J Obstet Gynaecol. 2002 Sep;109(9):1030–5.

74. Wald A, Ericsson M, Krantz E, Selke S, Corey L. Oral shedding of herpes simplex virus type 2. Sex Transm Infect. 2004 Aug;80(4):272–6.

75. Ashley RL. Sorting out the new HSV type specific antibody tests. Sex Transm Infect. 2001 Aug;77(4):232–7.

76. Ashley-Morrow R, Krantz E, Wald A. Time course of seroconversion by HerpeSelect ELISA after acquisition of genital herpes simplex virus type 1 (HSV-1) or HSV-2. Sex Transm Dis. 2003 Apr;30(4):310–4.

77. Rekabdar E, Tunbäck P, Liljeqvist JA, Lindh M, Bergström T. Dichotomy of glycoprotein g gene in herpes simplex virus type 1 isolates. J Clin Microbiol. 2002 Sep;40(9):3245–51.

78. Liljeqvist JA, Svennerholm B, Bergström T. Herpes simplex virus type 2 glycoprotein G-negative clinical isolates are generated by single frameshift mutations. J Virol. 1999 Dec;73(12):9796–802.

79. Daikoku T, Horiba K, Kawana T, Hirano M, Shiraki K. Novel deletion in glycoprotein G forms a cluster and causes epidemiologic spread of herpes simplex virus type 2 infection. J Med Virol. 2013 Oct;85(10):1818–28.

80. Eis-Hübinger AM, Däumer M, Matz B, Schneweis KE. Evaluation of three glycoprotein G2-based enzyme immunoassays for detection of antibodies to herpes simplex virus type 2 in human sera. J Clin Microbiol. 1999 May;37(5):1242–6.

81. Prince HE, Batterman HJ, Marlowe EM. Characterization of Serum Samples With Discordant Results in 2 Herpes Simplex Virus Type 2 IgG Assays. Sex Transm Dis. 2022 May 1;49(5):353–9.

82. Morrow R, Friedrich D. Performance of a novel test for IgM and IgG antibodies in subjects with culture-documented genital herpes simplex virus-1 or -2 infection. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2006 May;12(5):463–9.

83. Kim ID, Chang HS, Hwang KJ. Herpes simplex virus 2 infection rate and necessity of screening during pregnancy: a clinical and seroepidemiologic study. Yonsei Med J. 2012 Mar;53(2):401–7.

84. NHS England. Saving Babies’ Lives Version Three. 2023 Jul;3.1.

85. Sénat MV, Anselem O, Picone O, Renesme L, Sananès N, Vauloup-Fellous C, et al. Prevention and management of genital herpes simplex infection during pregnancy and delivery: Guidelines from the French College of Gynaecologists and Obstetricians (CNGOF). Eur J Obstet Gynecol Reprod Biol. 2018 May;224:93–101.

86. Brown EL, Morrow R, Krantz EM, Arvin AM, Prober CG, Yasukawa LL, et al. Maternal herpes simplex virus antibody avidity and risk of neonatal herpes. Am J Obstet Gynecol. 2006 Jul;195(1):115–20.

87. Nahmias AJ, Josey WE, Naib ZM, Freeman MG, Fernandez RJ, Wheeler JH. Perinatal risk associated with maternal genital herpes simplex virus infection. Am J Obstet Gynecol. 1971 Jul 15;110(6):825–37.

88. Nahmias AJ. Neonatal HSV infection Part I: continuing challenges. Herpes J IHMF. 2004 Aug;11(2):33–7.

89. National Institute for Health and Care Excellence. Intrapartum care for healthy women and babies: Clinical guideline [CG190]. 2014 updated 2022; Available from: https://www.nice.org.uk/guidance/cg190

90. National Institute for Health and Care Excellence. Preterm labour and birth: NICE guideline NG25. 2015 updated 2022; Available from: https://www.nice.org.uk/guidance/ng25

91. Major CA, Towers CV, Lewis DF, Garite TJ. Expectant management of preterm premature rupture of membranes complicated by active recurrent genital herpes. Am J Obstet Gynecol. 2003 Jun;188(6):1551–4; discussion 1554-5.

92. Utley K, Bromberger P, Wagner L, Schneider H. Management of primary herpes in pregnancy complicated by ruptured membranes and extreme prematurity: case report. Obstet Gynecol. 1987 Mar;69(3 Pt 2):471–3.

93. Dietrich YM, Napolitano PG. Acyclovir treatment of primary herpes in pregnancy complicated by second trimester preterm premature rupture of membranes with term delivery: case report. Am J Perinatol. 2002 Jul;19(5):235–8.

94. Thomson AJ, Royal College of Obstetricians and Gynaecologists. Care of Women Presenting with Suspected Preterm Prelabour Rupture of Membranes from 24+0 Weeks of Gestation: Green-top Guideline No. 73. BJOG Int J Obstet Gynaecol. 2019 Aug;126(9):e152–66.

95. Stock SJ, Thomson AJ, Papworth S, Royal College of Obstetricians and Gynaecologists. Antenatal corticosteroids to reduce neonatal morbidity and mortality: Green-top Guideline No. 74. BJOG Int J Obstet Gynaecol. 2022 Jul;129(8):e35–60.

96. Ehsanipoor RM, Major CA. Herpes simplex and HIV infections and preterm PROM. Clin Obstet Gynecol. 2011 Jun;54(2):330–6.

97. Sivarajah V, Venus K, Yudin MH, Murphy KE, Morrison SA, Tan DH. Does maternal HSV-2 coinfection increase mother-to-child transmission of HIV? A systematic review. Sex Transm Infect. 2017 Dec;93(8):535–42.

98. Aebi-Popp K, Bailey H, Malyuta R, Volokha A, Thorne C, Ukraine European Collaborative Study in EuroCoord. High prevalence of herpes simplex virus (HSV)- type 2 co-infection among HIV-positive women in Ukraine, but no increased HIV mother-to-child transmission risk. BMC Pregnancy Childbirth. 2016 Apr 27;16:94.

99. Drake AL, John-Stewart GC, Wald A, Mbori-Ngacha DA, Bosire R, Wamalwa DC, et al. Herpes simplex virus type 2 and risk of intrapartum human immunodeficiency virus transmission. Obstet Gynecol. 2007 Feb;109(2 Pt 1):403–9.

100. Warszawski J, Tubiana R, Le Chenadec J, Blanche S, Teglas JP, Dollfus C, et al. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS Lond Engl. 2008 Jan 11;22(2):289–99.

101. Bollen LJ, Whitehead SJ, Mock PA, Leelawiwat W, Asavapiriyanont S, Chalermchockchareonkit A, et al. Maternal herpes simplex virus type 2 coinfection increases the risk of perinatal HIV transmission: possibility to further decrease transmission? AIDS Lond Engl. 2008 Jun 19;22(10):1169–76.

102. Ouedraogo A, Nagot N, Vergne L, Konate I, Weiss HA, Defer MC, et al. Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial. AIDS Lond Engl. 2006 Nov 28;20(18):2305–13.

103. Patterson J, Hitti J, Selke S, Huang ML, Watts DH, Brown Z, et al. Genital HSV detection among HIV-1-infected pregnant women in labor. Infect Dis Obstet Gynecol. 2011;2011:157680.

104. Tosswill J. British HIV Association guidelines for the management of HIV in pregnancy and postpartum 2018 (2020 third interim update). :117.

105. Melvin AJ, Mohan KM, Schiffer JT, Drolette LM, Magaret A, Corey L, et al. Plasma and Cerebrospinal Fluid Herpes Simplex Virus Levels at Diagnosis and Outcome of Neonatal Infection. J Pediatr. 2015 Apr;166(4):827–33.

106. Niewiesk S. Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies. Front Immunol. 2014;5:446.

107. Royal College of Paediatrics and Child Health. Breastfeeding in the UK - position statement. 2017 updated 2022; Available from: https://www.rcpch.ac.uk/resources/breastfeeding-uk-position-statement

108. National Institute for Health and Care Excellence. Postnatal care: NICE guideline NG194. 2021; Available from: https://www.nice.org.uk/guidance/ng194

109. The Baby Friendly Initiative, UNICEF United Kingdom. Guide to the UNICEF UK baby friendly initiative standards. 2017; Available from: https://www.unicef.org.uk/babyfriendly/baby-friendly-resources/implementing-standards-resources/guide-to-the-standards/

110. The Royal College of Midwives. Position Statement: Infant feeding. 2018; Available from: https://www.rcm.org.uk/media/2289/infant-feeding.pdf

111. Taddio A, Klein J, Koren G. Acyclovir excretion in human breast milk. Ann Pharmacother. 1994 May;28(5):585–7.

112. Sheffield JS, Fish DN, Hollier LM, Cadematori S, Nobles BJ, Wendel GD. Acyclovir concentrations in human breast milk after valaciclovir administration. Am J Obstet Gynecol. 2002 Jan;186(1):100–2.

113. Drake AL, Roxby AC, Kiarie J, Richardson BA, Wald A, John-Stewart G, et al. Infant safety during and after maternal valacyclovir therapy in conjunction with antiretroviral HIV-1 prophylaxis in a randomized clinical trial. PloS One. 2012;7(4):e34635.

114. Whitley RJ. The use of antiviral drugs during the neonatal period. Clin Perinatol. 2012 Mar;39(1):69–81.

115. National Institute for Health and Care Excellence. British National Formulary for Children. 2023; Available from: https://bnfc.nice.org.uk/

116. National Institute for Health and Care Excellence. British National Formulary. 2023; Available from: https://bnf.nice.org.uk/

117. Kotronias D, Kapranos N. Detection of herpes simplex virus DNA in maternal breast milk by in situ hybridization with tyramide signal amplification. Vivo Athens Greece. 1999 Dec;13(6):463–6.

118. Sullivan-Bolyai JZ, Fife KH, Jacobs RF, Miller Z, Corey L. Disseminated neonatal herpes simplex virus type 1 from a maternal breast lesion. Pediatrics. 1983 Mar;71(3):455–7.

119. Parra J, Cneude F, Huin N, Bru CB, Debillon T. Mammary herpes: a little known mode of neonatal herpes contamination. J Perinatol Off J Calif Perinat Assoc. 2013 Sep;33(9):736–7.

120. Field SS. Fatal Neonatal Herpes Simplex Infection Likely from Unrecognized Breast Lesions. J Hum Lact Off J Int Lact Consult Assoc. 2016 Feb;32(1):86–8.

121. Koelle DM, Benedetti J, Langenberg A, Corey L. Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. Ann Intern Med. 1992 Mar 15;116(6):433–7.

122. Centers for Disease Control and Prevention. Breastfeeding: Herpes simplex virus. 2021; Available from: https://www.cdc.gov/breastfeeding/breastfeeding-special-circumstances/maternal-or-infant-illnesses/herpes.html

123. Wald A, Langenberg AGM, Krantz E, Douglas JM, Handsfield HH, DiCarlo RP, et al. The relationship between condom use and herpes simplex virus acquisition. Ann Intern Med. 2005 Nov 15;143(10):707–13.

124. Martin ET, Krantz E, Gottlieb SL, Magaret AS, Langenberg A, Stanberry L, et al. A pooled analysis of the effect of condoms in preventing HSV-2 acquisition. Arch Intern Med. 2009 Jul 13;169(13):1233–40.

125. Wald A, Langenberg AG, Link K, Izu AE, Ashley R, Warren T, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA. 2001 Jun 27;285(24):3100–6.

126. Magaret AS, Mujugira A, Hughes JP, Lingappa J, Bukusi EA, DeBruyn G, et al. Effect of Condom Use on Per-act HSV-2 Transmission Risk in HIV-1, HSV-2-discordant Couples. Clin Infect Dis Off Publ Infect Dis Soc Am. 2016 Feb 15;62(4):456–61.

127. Wald A, Selke S, Warren T, Aoki FY, Sacks S, Diaz-Mitoma F, et al. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. Sex Transm Dis. 2006 Sep;33(9):529–33.

128. Gupta R, Wald A, Krantz E, Selke S, Warren T, Vargas-Cortes M, et al. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis. 2004 Oct 15;190(8):1374–81.

129. Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med. 2004 Jan 1;350(1):11–20.

130. Wald A, Zeh J, Barnum G, Davis LG, Corey L. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med. 1996 Jan 1;124(1 Pt 1):8–15.

131. UK National Screening Committee. Antenatal screening for HSV-1 and HSV-2 infection to prevent neonatal herpes infection. 2018; Available from: https://view-health-screening-recommendations.service.gov.uk/genital-herpes/